Dr. Schiffman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
118 Med Surge # 1
Irvine, CA 92697Phone+1 949-824-6211Fax+1 949-824-4015
Education & Training
- Henry Ford Health/Henry Ford HospitalResidency, Ophthalmology, 1993 - 1996
- Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 1983 - 1986
- Universidad Autonoma de Ciudad JuarezClass of 1982
Certifications & Licensure
- CA State Medical License 2002 - 2025
- MI State Medical License 1984 - 2004
- American Board of Internal Medicine Internal Medicine
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
Publications & Presentations
PubMed
- 5 citationsEfficacy of a Preservative-Free Formulation of Fixed-Combination Bimatoprost and Timolol (Ganfort PF) in treatment-naïve Patients vs Previously Treated PatientsM Francesca Cordeiro, Ivan Goldberg, Rhett M. Schiffman, Paula Bernstein, Marina Bejanian
Clinical Ophthalmology. 2015-08-31 - 32 citationsBimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hyperte...Ivan Goldberg, Rafael Gil Pina, Aitor Lanzagorta-Aresti, Rhett M. Schiffman, Charlie Liu
The British Journal of Ophthalmology. 2014-07-01 - 137 citationsDexamethasone Intravitreal Implant in Combination with Laser Photocoagulation for the Treatment of Diffuse Diabetic Macular EdemaDavid Callanan, Sunil Gupta, David S. Boyer, Thomas A. Ciulla, Michael A Singer
Ophthalmology. 2013-09-01
Press Mentions
- Phase 3 Presbyopia Drop Trial LaunchesApril 6th, 2022
- Visus Therapeutics Appoints Industry Leaders Tracy Valorie and Dwight Moxie to Board of DirectorsAugust 25th, 2021
- Visus Therapeutics Expands Ophthalmic Drug Portfolio with Investigational Therapies for Glaucoma and Age-Related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery TechnologyAugust 19th, 2021
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: